Bone Abstracts

Osteogenesis imperfecta refers to a group of inherited disorders characterised by increased bone fragility, low bone mass and fragility fractures. Most patients carry mutations in the genes that encode type I collagen or other proteins involved in its post-translational modification. Bisphosphonates are widely used in the treatment of osteogenesis imperfecta but clinical trials have been powered to detect effects on BMD rather than fracture. In order to gain better understandi...

Osteogenesis imperfecta (OI) is a systemic connective tissue caused by mutations in collagen type 1 related genes. Patients with OI suffer from multiple fractures and various degrees of growth deficiency and bone deformity. Other symptoms are early hearing loss, abnormal dental tissue and hypermobility. It is not known whether the systemic effect of a defect collagen type 1 influences the quality of life in people with OI. We aimed to investigate health related quality of life...

Introduction: Aromatase inhibitors (AI) used as adjuvant treatment of hormone-sensitive breast cancer reduce the level of circulating estrogen and cause accelerated bone loss. The aim of this study is to investigate the prevalence of osteoporosis in women with breast cancer and the effect of chemotherapy on the risk of osteoporosis.Methods: Three hundred and sixty women with hormone-sensitive breast cancer who were scheduled to start treatment with AI we...

Osteogenesis imperfecta (OI) is a hereditary disease with a generalized involvement of the connective tissue caused by collagen type 1 mutations. The clinical appearance is broad with fractures as the key symptom. Only few genotype–phenotype correlations have been established. We aim to characterize the Danish OI population thoroughly including DXA and HRpQCT, anthropometry, patient history, and genetic background.This cross-sectional study includes...